Lilly, Novo Nordisk Present Promising Data in Type 2 Diabetes
June 28, 2021 Diabetes / Pharmaceuticals Eli Lilly’s investigational diabetes drug is showing significant promise in targeting A1C levels and weight loss in patients with type 2 diabetes, including those who had never been previously treated for the disease. All three doses of the investigational drug generated statistically significant results. Read Full Article on Biospace >>
Reveal the “Hidden Clinical Leaders” Who Drive HCP Network Adoption
June 28, 2021 Pharma / Clinical Development / HCPs Scientific and academic opinion leaders have major impacts on creating initial awareness and establishing treatment narratives, but don’t typically drive product adoption amongst Healthcare Provider communities. Ultimately, this creates a limited view of leadership in the traditional world of Key Opinion Leaders and does not paint the full picture needed to make decisions for your brand. The reality is that change in uptake is driven by regional and local clinical practice leaders – those who other HCPs trust and seek guidance from. Read Full Article on Biopharma Dive >>
J&J Enlists Veterans for Innovation Challenge Series Focused on Healthcare Solutions Created By, and For, Them
June 23, 2021 Marketing / Pharma / Innovation Johnson & Johnson is launching a first-ever pair of innovation challenges with military veterans in mind. The initial Quickfire “Veterans Lead” challenge is already underway and crowdsources health solutions from veterans, while the second is set to launch this week and aims to come up with ideas to better serve veterans. Watch On Youtube >> | Read Full Article on Fierce Pharma >>
HumanFirst, Duke Clinical Research Institute Validate Remote Monitoring for Clinical Trials
June 23, 2021 Clinical Development / Digital Innovation The news: HumanFirst (formerly Elektra Labs), a tech startup focused on building out remote clinical trials, and the Duke Clinical Research Institute (DCRI) are launching the Digital Measures Evaluation Center to assess how biometric sensors and other digital health measures can be best used in clinical trials. The new center will design and test how well digital sensors fit with different clinical trial designs to demonstrate both analytical and clinical validation for using wearables and biometric sensors in decentralized (remote) clinical trials. Read More on eMarketer >>
SHINE Medical Technologies Closes $150-million Series C-5 Financing to Advance Nuclear Fusion-Based Technologies
June 28, 2021 Oncology / Private Equity & Venture Capital SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing. Koch Disruptive Technologies (KDT) led the round, which also included participation by Fidelity Management & Research Company, Baillie Gifford and other new and current investors. The financing will support SHINE’s commercialization of its diagnostic and therapeutic medical isotope technologies and position the company for future growth as it works toward developing new fusion-based technology applications. Read Full Article on VentureBeat >>
Musculoskeletal Medical Startups Race to Enter Personalized Health Tech Market
June 25, 2021 Medical Startups / Innovation / 4IR “What’s happening in our society? Chronic diseases, chronic pain, diabetes and obesity,” she said. “That doesn’t require a magic pill and there’s not just a surgery. Oftentimes, there’s therapeutic components, behavior changes and movable touch points.” Enter personalized medicine. The buzzy yet powerful framing is growing in popularity among Silicon Valley startups. It’s a delivery system in which patients receive more holistic care that takes into account multiple symptoms or comorbidities. In hormonal health, for example, personalized medicine could add more data and specificity to which birth control someone takes, instead of the usual process of trial and error. Essentially, it’s the opposite of interventional medicine. Read Full Article on TechCrunch >>
CRISPR Injected into the Blood Treats a Genetic Disease for First Time June 26, 2021 CRISPR / Innovation / Gene Therapies The gene editor CRISPR excels at fixing disease mutations in lab-grown cells. But using CRISPR to treat most people with genetic disorders requires clearing an enormous hurdle: getting the molecular scissors into the body and having it slice DNA in the tissues where it’s needed. Now, in a medical first, researchers have injected a CRISPR drug into the blood of people born with a disease that causes fatal nerve and heart disease and shown that in three of them it nearly shut off production of toxic protein by their livers. Read Full Article on Science >>
Protein That Puts the Brakes on Fat Burning Could Be Obesity Drug Target
June 28, 2021 Obesity / Preclinical Research A protein called Them1 prevents fat burning in cells by blocking access to the fuel source, according to preclinical research by Weill Cornell Medicine/NewYork-Presbyterian and Harvard Medical School/Beth Israel Deaconess Medical Center investigators. The findings may contribute to the development of a new type of obesity treatment that targets this response. Read Full Article on >>
American Diabetes Association Release: Weekly Injection Of Glucose-Reducing Drug Offers Safe And Effective Way To Significantly Reduce Cardiorenal Events For People With Type 2 Diabetes
June 28, 2021 Diabetes / Clinical Development Data released today from a large-scale, international clinical trial show significant reduction in the first occurrence of a heart attack, stroke, or death, and a reduction in progression of kidney disease in patients with type 2 diabetes with weekly use of efpeglenatide, an injectable drug with glucose- and weight-lowering effects. The findings were presented at the virtual 81st Scientific Sessions of the American Diabetes Association® (ADA) and simultaneously published in The New England Journal of Medicine. Read Full American Diabetes Association Release >>
Controversial Alzheimer’s Drug Could Cost US $334B — Nearly Half of DoD Budget
June 28, 2021 Neurology / Alzheimer’s / Pharmaceuticals Despite unproven efficacy, Biogen set the drug’s list price at $56,000 per year. Concern is mounting over the price of the controversial new Alzheimer’s drug Aduhelm. Advocates, lawmakers, and critics worry in particular about what the drug’s $56,000 per-year list price will do to Medicare. The federal insurance program is available to those age 65 and over, which covers the vast majority of the roughly 6 million adults with Alzheimer’s in the US. Read Full Article on Ars Technica >>